Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 (Incorporated in Bermuda with limited liability) ) ( 於百慕達註冊成立之有限公司 (Stock Code 股份代號: 767) N O T I F I C AT I O N L E T T E R Dear Non-registered holders(Note 1) Zhong Ji Longevity Science Group Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock ...

Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 (Incorporated in Bermuda with limited liability) ( 於百慕達註冊成立之有限公司 ) (Stock Code 股份代號: 767) N O T I F I C AT I O N L E T T E R Dear Registered Shareholders, 26 September 2025 Zhong Ji Longevity Science Group Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of ...

Dividend and Financial Performance - The Company did not declare an interim dividend for the six months ended June 30, 2025, consistent with the previous year[11]. - For HY2025, the Group recorded total revenue of HK$47,973,000, an increase from HK$42,403,000 in HY2024[32]. - The Group reported a loss of HK$12,922,000 for HY2025, compared to a loss of HK$917,000 in HY2024[32]. - The longevity science business generated revenue of HK$34,253,000 but incurred a segment loss of HK$10,945,000 for HY2025[32]. - The money lending and financial advisory business had static revenue of HK$13,720,000 and a segment profit of HK$12,306,000 for HY2025[37]. - The Group's basic and diluted loss per share was HK$2.29 cents as of June 30, 2025, compared to HK$0.2 cents on June 30, 2024[33]. - The revenue from the longevity science business segment amounted to approximately HK$34,253,000 for HY2025, an increase from HK$25,180,000 in HY2024[84]. - The segment incurred a loss of approximately HK$10,945,000 in HY2025, compared to a loss of HK$4,342,000 in HY2024, primarily due to unforeseen events and operational challenges post-pandemic[88]. Business Operations and Strategy - The Company is diversifying its business and has become Asia's first one-stop health and longevity center since late 2022[12]. - The Company is focusing on expanding its longevity science business alongside its existing financial services[12]. - The Group is focusing on diversifying into promising longevity medical health businesses to enhance financial performance[26]. - The Company engaged Dongwei Law Firm to expedite the recovery of overdue loans from strategic partners, extending the service contract for an additional 36 months in August 2024[20]. - The restructuring of Tian Xing has been completed, restoring business partnerships and banking authority operations by June 2023[14]. - The Group plans to monetize portions of its loan portfolio with strategic partners Fanhua and Haier through ongoing negotiations[40]. - The Group has engaged with strategic partners to negotiate the monetization of parts of the loan portfolio, indicating ongoing market expansion efforts[42]. Loan Management and Recovery - The overdue loans from strategic partners are being managed with partial initial loan principals supplied by the Company[21]. - The strategic partner loans are being managed to recover overdue amounts, with RMB$6.7 million cash recovered from two borrowers[38]. - The recovery actions for impaired loans have entered a review assessment stage, highlighting the company's commitment to recovering outstanding amounts[46]. - The Independent Recovery Committee has successfully recovered gross proceeds from two borrower entities of four loans out of the 36 long-impaired loans, although the recovery process is still ongoing[45]. - The outstanding loans previously impaired amounted to approximately HK$1,076,000,000 as of December 31, 2019, with recovery efforts ongoing since August 2022[46]. Customer and Revenue Concentration - The top five customers accounted for approximately 51% of total revenue in HY2025, up from 33% in HY2024, with the largest customer contributing about 30% of total revenue, compared to 24% in HY2024[49]. - As of June 30, 2025, the largest customer and the top five customers accounted for 40% and 89% of the total gross loan receivables balance, respectively[49]. - The top five borrowers under the Strategic Partners Business Model accounted for approximately 20.13% of the entire other receivables of the Group as of June 30, 2025, up from 12.917% as of December 31, 2024[74]. - The top five borrowers under the Corporate and Personal Borrowers Business Model accounted for approximately 79.38% of the entire loan and interest receivables of the Group as of June 30, 2025, down from 89.19% as of December 31, 2024[82]. Financial Position and Assets - As of June 30, 2025, the Group's consolidated net assets were HK$431,540,000, up from HK$400,139,000 on December 31, 2024[33]. - As of June 30, 2025, the Group's net current assets were approximately HK$405,862,000, an increase from HK$372,047,000 as of December 31, 2024[97]. - Cash and bank balances as of June 30, 2025 were approximately HK$30,036,000, down from HK$47,842,000 as of December 31, 2024[100]. - The Group's bank and other borrowings decreased to HK$9,105,000 as of June 30, 2025, compared to HK$11,541,000 as of June 30, 2024[102]. - As of June 30, 2025, strategic partners loan assets were approximately HK$178,004,000 before impairments, with a net carrying value of approximately HK$113,422,000[74]. - The corporate and personal borrowers business loan assets were approximately HK$865,512,000 before impairments, with a net carrying value of approximately HK$228,801,000 as of June 30, 2025[82]. Share Capital and Employee Information - The total number of issued ordinary shares increased to 636,654,300 as of June 30, 2025, up from 546,529,549 as of December 31, 2024[103]. - The Group's employee count decreased to approximately 52 as of June 30, 2025, from 55 as of December 31, 2024[120]. - Employee benefits expense, excluding Directors' emoluments, was approximately HK$8.2 million in HY2025, representing an increase of about 29.8% compared to HK$6.3 million in HY2024[117]. Share Option and Award Schemes - The 2012 Share Option Scheme has 3,868,000 outstanding share options as of June 30, 2025, with an exercise period from December 31, 2023, to December 30, 2030[151]. - The 2022 Share Option Scheme allows the Board to grant options to qualifying participants, with the exercise price complying with Listing Rules[151]. - The total number of shares available for issue under the 2022 Share Option Scheme represents approximately 6.1% of the ordinary shares of the Company in issue[170]. - The Share Award Scheme was adopted on May 18, 2021, to recognize contributions and provide incentives for participants[188]. - The maximum number of restricted shares that may be awarded under the Share Award Scheme shall not exceed 38,680,000 shares, which is capped at 10% of the issued share capital of the Company[195].

中基长寿科学(00767)发布公告，于2025年9月13日，本公司的间接非全资附属公司中骊(海南)生命科学 技术有限公司(中骊海南)与海南博鳌超级医院有限公司(海南博鳌)签署合作协议(合作协议)，中骊海南与 海南博鳌双方共同建立"国际肿瘤精准医学中心"(医学中心)，海南博鳌负责提供中心的场地及提 供"1+X"平台的服务功能，包括但不限于：门诊、住院、检查、治疗、手术等，中骊海南负责中心的营 运并提供专家及专科技术和专科设备支援，双方共同为患者开展诊疗活动及各种科研项目。 董事会认为健康长寿科学市场的前景广阔，因为观察到全球的富裕客户更愿意接受及花费在长寿科学应 用上，以提升彼等的整体健康及免疫状况，并促进彼等身体年轻化。 签署合作协议符合本集团的长寿科学业务发展策略及计划，将有利于本集团未来的业务发展，为本集团 进一步拓展国内市场奠定了坚实的基础。董事会相信签署合作协议进一步完善本集团在长寿科学诊断及 医疗服务领域的布局，为本集团开拓新的长寿科学收入来源，以期长远为本集团带来更加稳定及持续增 长的收入。 ...

签署合作协议符合本集团的长寿科学业务发展策略及计划，将有利于本集团未来的业务发展，为本集团 进一步拓展国内市场奠定了坚实的基础。董事会相信签署合作协议进一步完善本集团在长寿科学诊断及 医疗服务领域的布局，为本集团开拓新的长寿科学收入来源，以期长远为本集团带来更加稳定及持续增 长的收入。 董事会认为健康长寿科学市场的前景广阔，因为观察到全球的富裕客户更愿意接受及花费在长寿科学应 用上，以提升彼等的整体健康及免疫状况，并促进彼等身体年轻化。 智通财经APP讯，中基长寿科学(00767)发布公告，于2025年9月13日，本公司的间接非全资附属公司中 骊(海南)生命科学技术有限公司(中骊海南)与海南博鳌超级医院有限公司(海南博鳌)签署合作协议(合作 协议)，中骊海南与海南博鳌双方共同建立"国际肿瘤精准医学中心"(医学中心)，海南博鳌负责提供中心 的场地及提供"1+X"平台的服务功能，包括但不限于：门诊、住院、检查、治疗、手术等，中骊海南负 责中心的营运并提供专家及专科技术和专科设备支援，双方共同为患者开展诊疗活动及各种科研项目。 ...

Group 1 - The company, Zhongji Changshou Science (00767.HK), has signed a cooperation agreement with Hainan Boao Super Hospital to establish an "International Precision Medicine Center for Oncology" [1] - Hainan Boao will provide the center's facilities and services, while Zhongji Changshou will manage operations and provide expert support and specialized equipment [1] - The Boao Super Hospital is recognized as a pioneer in China's medical field, leveraging special policies to utilize advanced foreign medical technologies and services [1] Group 2 - The board believes that the market for longevity science is promising, as affluent clients are increasingly willing to invest in longevity applications to enhance their health and vitality [2] - The cooperation agreement aligns with the company's strategy for developing longevity science, laying a solid foundation for future business expansion in the domestic market [2] - The agreement is expected to enhance the company's positioning in the longevity science diagnostic and medical service sectors, creating new revenue streams for stable and sustainable growth [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 自願公告 合作協議 本公告由中基長壽科學集團有限公司（「本公司」，連同其附屬公司，「本集團」）自願 作出。 合作協議 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二五年九月十三日，本公司之 間接非全資附屬公司中驪（海南）生命科學技術有限公司（「中驪海南」）與海南博鼇超 級醫院有限公司（「海南博鼇」）簽署合作協議（「合作協議」），據此，中驪海南與海南 博鼇雙方共同建立「國際腫瘤精準醫學中心」（「醫學中心」），海南博鼇負責提供中心 的場地及提供「1+X」平台的服務功能，包括但不限於：門診、住院、檢查、治療、 手術等，中驪海南負責中心的營運並提供專家及專科技術和專科設備支援，雙方共 同為患者開展診療活動及各種科研項目。 – 1 – 關於海 ...

Group 1 - The core point of the article is that Zhongji Changshou Science (00767.HK) has extended the deadline for the memorandum of understanding regarding the acquisition of 100% equity in the Comprehensive Cell Bank Limited from October 2, 2025, to December 2, 2025, due to the need for additional time for due diligence and evaluation of the seller [1] - The target company is collaborating with Bright Cells Inc. in the United States on FDA-approved clinical research involving stem cells [1] - The collaboration aims to conduct clinical studies on mesenchymal stem cell treatments for aging and premature ovarian failure in regions including the United States, Hong Kong, Macau, Taiwan, Dubai, Malaysia, and Cambodia [1] Group 2 - If the acquisition is finalized, it may constitute a transaction that requires disclosure under the listing rules and could be considered a connected transaction [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Zhong Ji Longevity Science Group Limited 中基長壽科學集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：767） 延長有關可能收購事項之諒解備忘錄之到期日 本公告乃中基長壽科學集團有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨 條例第XIVA部項下內幕消息條文作出。 茲提述本公司日期為二零二五年八月四日的公告（「該公告」），內容分別有關（其中 包括）就收購亞洲綜合細胞庫有限公司股權總額之100%訂立諒解備忘錄及延長有關 可能收購事項之諒解備忘錄之到期日。除非文義另有所指，否則本公告所用專有詞 彙與該公告所界定者具有相同涵義。 誠如該公告所披露，諒解備忘錄將於二零二五年十月二日或最終協議簽立時（以較 早者為準）到期，除非經買方與賣方以書面方式協定延長，則另 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中基長壽科學集團有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00767 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 40,000,000,000 | HKD | | 0.01 | HKD | | 400,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 40,000,000,000 | HKD ...